IDH2 and central nervous system cancer: Initially identified in the rare neurological disorder 2‐hydroxyglutaric aciduria, D‐2‐Hydroxyglutarate (2‐HG) gained significant attention in 2009, when genome‐wide sequencing of gliomas and acute myeloid leukemia (AML), coupled with groundbreaking research on isocitrate dehydrogenases (IDH), uncovered its synthesis by mutated IDH1 (mIDH1) or IDH2 (mIDH2) enzymes.159, 160, 161, 162, 163, 164